The two regulatory frameworks for compounding pharmacies have different quality standards, oversight, and use cases. Knowing which one fills your prescription matters.
Safety & RegulationJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Both 503A and 503B pharmacies can lawfully compound GLP-1 medications. The framework affects scale, quality controls, and oversight. 503B facilities have more rigorous standards but are less common.
NexLife's six-pharmacy network includes both 503A and 503B partners:
503A: Strive (AZ)
503B: Medivera (MO), Absolute (OH), RedRock (UT)
Both: Empower (TX), Hallandale (FL)
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.